Top Story Today
GSK Dropped $10.6 Billion to Buy Its Way Back Into Cancer
A company that walked away from oncology is now writing one of the biggest checks in cancer history. GSK is acquiring Nuvalent for approximately $10.6 billion in equity value (a 40% premium) to get two lung cancer drugs already under FDA review, with decisions expected in September and November. The drugs target specific genetic mutations in non-small cell lung cancer, and clinical data is strong: a 68% response rate in one hard-to-treat subgroup. But Wall Street sees a tight margin for error. GSK shares dipped 2.5-3.5% on the news, and analysts warn that neither drug may reach mega-blockbuster status.
Why it matters: With its blockbuster HIV drug losing patent protection in early 2028, GSK needs new revenue engines fast. This deal joins a wave of precision oncology acquisitions (Sanofi-Blueprint, Genmab-Merus, Merck-Terns) confirming that big pharma sees genetically targeted cancer drugs as the future of the field.
Read more →Clinical and Regulatory Breakthroughs
The Drug That Wakes Up a Sleeping Giant in Neuroscience
For 26 years, scientists knew exactly what causes narcolepsy but couldn't build a pill to fix it. Now two companies have cracked it. Takeda's orexin-2 agonist boosted wakefulness by over 26 minutes versus placebo in Phase 2b, with an FDA decision due Q3 2026. Alkermes followed with the first positive Phase 2 results in narcolepsy type 2, a condition no orexin drug had tackled before.
Read more →The Antibiotic That Finally Escaped the IV Pole
For decades, the most powerful antibiotic class (carbapenems) could only be given through an IV in the U.S. The FDA just approved Utebzi, the first oral carbapenem available in the United States, for complicated UTIs caused by drug-resistant bacteria. In trials, the pill matched IV therapy so convincingly that an independent committee stopped the study early for efficacy.
Read more →First New Antifungal Class in 20 Years Clears Phase 3
ICU mortality for invasive aspergillosis can top 90%, and doctors have been fighting it with the same drug classes since the early 2000s. F2G and Shionogi's olorofim, which attacks fungal DNA machinery instead of cell walls, matched standard IV therapy in Phase 3 with nearly half the side effects. Regulatory filings are expected by year-end.
Read more →One DNA Letter, One Potential Fix: Beam Gets FDA Green Light for Base Editing in PKU
The FDA cleared Beam Therapeutics to test BEAM-304, a base-editing gene therapy that corrects a single DNA typo causing phenylketonuria (PKU), a disease forcing patients into lifelong brutal dietary restriction. It's a landmark step for base editing, essentially molecular spell-check that fixes one letter without cutting the DNA strand, now entering clinical development for a metabolic disease.
Read more →Deals and M&A
Lilly's Shopping Spree Finds a Painkiller That Skips the Opioid Problem
Eli Lilly quietly acquired 4E Therapeutics, a startup with a first-in-class painkiller that mutes pain signals in peripheral nerves without ever touching the brain. It's the latest in Lilly's 2026 acquisition spree (10 deals totaling over $25 billion), all funded by the GLP-1 cash machine. The lead drug just cleared Phase 1; the non-opioid pain market is projected to hit $70 billion by 2030.
Read more →Biogen Pays Up to $1 Billion for a Company With Zero Clinical-Stage Drugs
Biogen is spending up to $1 billion on RayThera, a stealth-mode startup with three preclinical anti-inflammatory assets. It's the latest move in Biogen's dramatic pivot from neurology into immunology, driven by a shrinking MS franchise. The founders previously sold two companies to pharma giants using the same playbook.
Read more →Jazz Commits Up to $4 Billion for Drugs That Don't Exist Yet
Jazz Pharmaceuticals and AbCellera signed a deal worth up to $4 billion across as many as five programs to discover T-cell engagers for solid tumors, particularly GI cancers. Only $84 million changes hands near-term; the rest is milestone-dependent. The option-style structure gives Jazz shots at up to five programs with limited downside, targeting one of oncology's hardest unsolved problems.
Read more →Funding and Policy
The MyoKardia Crew Rides Again With a $400 Million IPO
The team behind MyoKardia's $13 billion sale to Bristol Myers Squibb just pulled off one of 2026's biggest biotech IPOs. Kardigan priced 25 million shares at $16 (top of range), raising $400 million for three cardiovascular programs targeting diseases with zero approved treatments. The deal priced at a 25% discount to its Series B, a sign that public investors still demand disciplined entry points.
Read more →A Top VC Tells Washington to Back Off China Biotech
Canaan partner Julie Grant went public against proposed legislation (BINSA) that would extend U.S. outbound investment screening to biotechnology for the first time. Cross-border licensing from Greater China hit $136 billion in 2025, roughly a third of global deal value. Grant argues restrictions will slow American drug development more than they protect national security.
Read more →